# Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)

> **NCT02652520** · PHASE1 · COMPLETED · sponsor: **University Hospital, Brest** · enrollment: 60 (actual)

## Conditions studied

- End Stage Renal Diseases

## Interventions

- **PROCEDURE:** HEMO2Life® use in organ preservation solution

## Key facts

- **NCT ID:** NCT02652520
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2018-02-23
- **Final completion:** 2018-02-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652520, "Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02652520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*